NCT00828971

A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs

A Prospective, Randomized, Open Label, Active Comparator, Multicenter, National Trial to Compare the Efficacy and Safety of Sequential IV/PO Moxifloxacin 400 mg Once Daily Versus IV Amoxicillin/Clavulanate 2,0/0,2 g Every 8 Hours Followed by Oral Amoxicillin/Clavulanate 875/125 mg Every 8 Hours in the Treatment of Adult Subjects With Complicated Skin and Skin Structure Infections

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess if a therapy with intravenous and oral moxifloxacin is as effective as a therapy with intravenous and oral amoxicilline/clavulanate in the treatment of complicated skin and skin structure infection.

Conditions

• Infectious Diseases

Interventions

Type	Name	Description
DRUG	Avelox (Moxifloxacin, BAY12-8039)	Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.
DRUG	Amoxicilline/clavulanic	IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days

Timeline

• Start date: 2008-11-01
• Primary completion: 2009-09-01
• Completion: 2009-10-01
• First posted: 2009-01-26
• Last updated: 2014-12-08

Locations

22 sites across 1 country: Italy